Loading clinical trials...

COMPLETEDNA

COVID-19 Seroprevalence Study in French Guiana

NCT04490850•Institut Pasteur

Summary

Detailed Description

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana. This study is a interventional study that present minimal risks and constraints. The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;
•State of health compatible with a blood sample as defined in the protocol

Exclusion Criteria

•Inability to consent
•Person under guardianship or curatorship
•Known pathology or a health problem contraindicated with the collect of blood sample.

Locations (5)

Centre Hospitalier Andrée Rosemon

Cayenne, French Guiana

Laboratoire de biologie méicale, Institut Pasteur de la Guyane

Cayenne, French Guiana

Laboratoires Eurofins Guyane

Cayenne, French Guiana

Laboratoire de biologie médicale de Kourou

Kourou, French Guiana

Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni

Saint-Laurent-du-Maroni, French Guiana

Key Dates

Start Date

July 15, 2020

Primary Completion Date

September 24, 2021

Completion Date

September 24, 2021

Last Updated

February 15, 2022

Enrollment

3,541

ACTUAL participants

Conditions

Coronavirus InfectionSevere Acute Respiratory SyndromeSARS-CoV InfectionCovid19

Interventions

Blood sample

PROCEDURE

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287

Long COVIDSars-CoV-2 Infection+2 more

View study

RECRUITING

Post COVID-19 Biorepository

NCT04885504

Coronavirus Infection

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 15, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

COVID-19 Seroprevalence Study in French Guiana

Inclusion Criteria

Exclusion Criteria

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Post COVID-19 Biorepository

Capturing MultiORgan Effects of COVID-19

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

Effect of a Vaccination Against COVID-19 on Monocyte Production of Oxygenated Derivatives.